Log in

NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, Forecast & News

$376.42
+4.26 (+1.14 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$372.56
Now: $376.42
$379.18
50-Day Range
$304.21
MA: $345.50
$376.46
52-Week Range
$271.37
Now: $376.42
$442.00
Volume974,273 shs
Average Volume772,003 shs
Market Capitalization$41.33 billion
P/E Ratio19.01
Dividend YieldN/A
Beta1.2
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:REGN
CUSIP75886F10
Phone914-847-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.71 billion
Cash Flow$22.38 per share
Book Value$80.34 per share

Profitability

Net Income$2.44 billion

Miscellaneous

Employees7,400
Market Cap$41.33 billion
Next Earnings Date2/5/2020 (Estimated)
OptionableOptionable

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.


Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

How will Regeneron Pharmaceuticals' stock buyback program work?

Regeneron Pharmaceuticals announced that its board has initiated a share buyback plan on Tuesday, November 5th 2019, which allows the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 2.9% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's leadership believes its stock is undervalued.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) released its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported $6.67 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $5.13 by $1.54. The biopharmaceutical company had revenue of $2.05 billion for the quarter, compared to analyst estimates of $1.98 billion. Regeneron Pharmaceuticals had a net margin of 28.13% and a return on equity of 24.85%. The firm's quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $5.87 EPS. View Regeneron Pharmaceuticals' Earnings History.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Regeneron Pharmaceuticals.

What price target have analysts set for REGN?

19 brokers have issued 1-year target prices for Regeneron Pharmaceuticals' stock. Their forecasts range from $320.00 to $453.00. On average, they expect Regeneron Pharmaceuticals' share price to reach $389.44 in the next twelve months. This suggests a possible upside of 3.5% from the stock's current price. View Analyst Price Targets for Regeneron Pharmaceuticals.

What is the consensus analysts' recommendation for Regeneron Pharmaceuticals?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 10 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Regeneron Pharmaceuticals.

What are Wall Street analysts saying about Regeneron Pharmaceuticals stock?

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Regeneron’s third-quarter results were impressive as the company beat on both sales and earnings, driven by the label expansion of blockbuster drug Eylea and strong Dupixent sales in moderate-to-severe atopic dermatitis and asthma. The company’s efforts to expand the label of its approved drugs Eylea and Dupixent, and concurrently develop the pipeline are encouraging. The immuno-oncology platform, which includes Libtayo and a wide portfolio of bispecific antibodies, is progressing well too. However, the company is highly dependent on Eylea for growth and the drug is expected to face competition by the end of the year, which will adversely impact sales. Pipeline setbacks are a concern as well. Shares have underperformed the industry in the year so far." (11/11/2019)
  • 2. Cantor Fitzgerald analysts commented, "We see potential for the pipeline long-term, but from a stock perspective we see more headwinds than tailwinds over the next 12 months for the base business. We think that concerns around competition will continue to be an overhang over 2019 with late-stage readouts in atopic dermatitis. Although we see some potential near-term catalysts with asthma and nasal polyps, we would like to see the hematology and oncology pipeline story emerge a bit more. Valuation Summary We have a 12-month price target of $415 on REGN shares." (2/6/2019)

Has Regeneron Pharmaceuticals been receiving favorable news coverage?

Media headlines about REGN stock have trended somewhat positive this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Regeneron Pharmaceuticals earned a news impact score of 1.7 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Regeneron Pharmaceuticals.

Are investors shorting Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 2,360,000 shares, an increase of 5.8% from the November 14th total of 2,230,000 shares. Based on an average daily trading volume, of 769,900 shares, the short-interest ratio is presently 3.1 days. Approximately 2.9% of the shares of the company are sold short. View Regeneron Pharmaceuticals' Current Options Chain.

Who are some of Regeneron Pharmaceuticals' key competitors?

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Netflix (NFLX), Celgene (CELG), Gilead Sciences (GILD), Biogen (BIIB), Alibaba Group (BABA), NVIDIA (NVDA), Tesla (TSLA), Amgen (AMGN), Alphabet (GOOG) and Broadcom (AVGO).

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the folowing people:
  • Dr. Schleifer Leonard S., Co-Founder, Pres, CEO & Exec. Director (Age 66)
  • Dr. George D. Yancopoulos, Founding Scientist, Pres, Chief Scientific Officer & Director (Age 59)
  • Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 55)
  • Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 46)
  • Ms. Marion E. McCourt, Sr. VP & Head of Commercial (Age 59)

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (3.22%), Pictet Asset Management Ltd. (0.55%), Sumitomo Mitsui Trust Holdings Inc. (0.43%), Point72 Asset Management L.P. (0.40%), Candriam Luxembourg S.C.A. (0.38%) and First Trust Advisors LP (0.27%). Company insiders that own Regeneron Pharmaceuticals stock include Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Which institutional investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., First Trust Advisors LP, Point72 Asset Management L.P., Chevy Chase Trust Holdings Inc., Stifel Financial Corp, Commerzbank Aktiengesellschaft FI, Parametric Portfolio Associates LLC and Virginia Retirement Systems ET AL. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Christopher R Fenimore, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Which institutional investors are buying Regeneron Pharmaceuticals stock?

REGN stock was bought by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Russell Investments Group Ltd., State Street Corp, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc. and Candriam Luxembourg S.C.A.. View Insider Buying and Selling for Regeneron Pharmaceuticals.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $376.42.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $41.33 billion and generates $6.71 billion in revenue each year. The biopharmaceutical company earns $2.44 billion in net income (profit) each year or $19.80 on an earnings per share basis. Regeneron Pharmaceuticals employs 7,400 workers across the globe.View Additional Information About Regeneron Pharmaceuticals.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is http://www.regeneron.com/.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]


MarketBeat Community Rating for Regeneron Pharmaceuticals (NASDAQ REGN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  1,285 (Vote Outperform)
Underperform Votes:  1,138 (Vote Underperform)
Total Votes:  2,423
MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe REGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel